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a b s t r a c t
Cardiovascular diseases (CVD) are the most frequent cause of death in developed countries. Their
prevalence is higher in several chronic inﬂammatory conditions. This is likely due to the substantial
contribution of the inﬂammatory status of the patients to the development and stability of atheroscle-
rotic plaques. Recent evidence suggests that interleukin (IL)-32 may be involved in the conditions that
contribute to CVD. IL-32 not only modulates important inﬂammatory pathways known to contribute to
the pathogenesis of both inﬂammatory diseases and atherosclerosis, including tumor necrosis factor
(TNF)a, IL-6 or IL-1b, but it has been also suggested to modulate endothelial cell function and the serum
concentration of high-density lipoprotein (HDL). In this review, we highlight the recent advances in the
ﬁeld of IL-32 in relation to chronic inﬂammatory disorders and argue for a role of IL-32 in the increased
prevalence of CVD in these patients.
© 2017 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).
1. Introduction
In general, acute inﬂammation is a positive reaction of the body
to insults such as traumatic tissue injury or invading pathogens.
When an immune response is triggered, it can lead to eradication of
the pathogen or facilitate turnover, adaptation and repair of the
tissues involved. In contrast, during chronic inﬂammation, these
responses are usually low grade but persistent, resulting in tissue
damage and degeneration [1]. Circulating elevated markers such as
interleukin (IL)-1b and IL-6 are upstream of the biomarker C-
reactive protein (CRP) and are known to be associated with on-
going low grade inﬂammation [2,3]. Moreover, immune cells from
both innate- and adaptive immunity (monocytes, neutrophils,
macrophages and T/B cells) have been suggested to play a role in
chronic inﬂammatory conditions and are responsible for the main
production of a wide spectrum of pro-inﬂammatory cytokines such
as TNFa, IL-1b and IL-6 and IL-17. These pro-inﬂammatory cyto-
kines may trigger other inﬂammatory responses and immune cell
activation, leading to an ongoing inﬂammatory process.
The pathophysiology of many chronic inﬂammatory diseases,
including rheumatoid arthritis (RA), chronic obstructive pulmonary
disease (COPD), inﬂammatory bowel disease (IBD) and athero-
sclerosis, has been thoroughly studied in the past years. Interest-
ingly, the development of cardiovascular diseases (CVD) have
emerged as a serious concern in these patients [4]. For patients, it
represents the leading cause of death, accounting for approxi-
mately one-third to one-half of all RA-related deaths (1; 2) [4e6]. It
seems that persistent inﬂammation plays a major role in the
development of CVD and atherosclerosis. Over the past years,
atherosclerosis has been increasingly regarded as an inﬂammatory
disease, with dyslipidemia representing only one (albeit important)
of its inducers [7]. Furthermore, a direct interaction between
inﬂammation and lipids has been well-documented. Circulating
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cholesterol levels may correlate with disease activity, which can
result in a change in lipid composition during periods of a higher
inﬂammatory state, favouring formation of atherosclerotic plaques
in the case of RA patients [8e10].
Interleukin-32 has been described as a pro-inﬂammatory cyto-
kine involved in the pathogenesis of several inﬂammatory diseases.
It is known to play a role in RA due to its capacity to induce TNFa,
which is a major cytokine in RA. Additionally, IL-32 contributes to
the induction of other pro-inﬂammatory mediators such as IL-1b-
induced ICAM-1 upregulation in human umbilical endothelial cells
(HUVECs) and was later found to be expressed in atherosclerotic
plaques [11,12]. IL-32 is also highly expressed in T cells, known to
play an important role in the late stages of atherosclerosis, char-
acterized by plaque instability and rupture. Given these facts, one
may hypothesize that IL-32 could be an important contributing
factor to the development of CVD in individuals suffering from
chronic inﬂammatory conditions. Knowledge on the involvement
of the innate and adaptive immune systems in the pathogenesis of
chronic inﬂammatory conditions and CVD has greatly expanded in
the last years. Nevertheless, the higher incidence of CVD in chronic
inﬂammatory conditions is still an important unmet clinical need.
Therefore, it is essential to get a better understanding of this
complex interaction in these conditions.
In this review, we discuss the recent insights of the role of IL-32
in the pathogenesis of autoimmune diseases focusing on RA, COPD
and IBD. Additionally, the potential role of IL-32 in the development
of atherosclerosis, as pre-clinical condition of CVD, will be dis-
cussed. Finally, we will argue for an important role of IL-32 in the
increased prevalence of cardiovascular diseases within these
chronic inﬂammatory conditions.
2. Interleukin-32: history and function
In 1992 Dahl et al. discovered a molecule that was called natural
killer cell transcript 4 (NK4). Gene expression of NK4 was increased
when peripheral blood mononuclear cells (PBMCs), especially NK
or mitogen-stimulated T cells, were exposed to a high dose of
interleukin-2 (IL-2) [13,14]. Moreover, it was hypothesized that NK4
could play a role in cell adhesion since it contains an Arg-Gly-Asp
(RGD) sequence, which is important for mediating cell adhesion
for a variety of proteins [15]. Nevertheless, the function of NK4
remained unknown until 2005. Kim et al. then showed that re-
combinant NK4 induced TNFa production in Raw 264.6 macro-
phages showing classical pro-inﬂammatory properties leading to
renaming the molecule to interleukin-32 (IL-32) [16]. Additionally,
the genomic structure and localization of IL-32 was explored. In
humans, IL-32 resides on chromosome 16 p13.3 and consists of
eight small exons. Besides mammals, IL-32 is expressed in other
species like bovine and swine, but not in mice. Moreover, IL-32 can
be spliced at mRNA level by alternative splicing, generating at least
six different isoforms: IL32g, IL32b, IL32a, IL-32d, IL-32z and IL-32ε,
of which not all functions are known yet [17]. The receptor for IL-32
has not yet been discovered, although binding of IL-32 to proteinase
3 and integrins, aVb3 and aVb6, has been described [17,18]. In
addition, in the presence of functional aVb3, recombinant IL32g
induced in vitro endothelial cell tube formation showing a role for
IL-32 in angiogenesis [19]. The total IL-32 protein can be induced by
IFN-y and besides TNFa, IL-32 can also stimulate IL-8 production by
activation of signaling pathways nuclear factorekB (NF-kB) and p38
mitogen-activated protein (MAP) kinase [16]. The intra-cellular
nucleotide-binding oligomerization domain (NOD)1 and NOD2 li-
gands can also synergize with IL-32 for IL-6 and IL-1b production
through a caspase 1-dependent mechanism [20] (Fig. 1). In
contrast, silencing of endogenous IL-32 shows attenuated IL-1b, IL-
6, IL8 and TNFa production in endothelial cells and monocytes [11].
IL-32 acts as a pro-inﬂammatory cytokine and an endogenous
regulator of cytokine production. Although the knowledge on the
functions of IL-32 has expanded signiﬁcantly in the last decade,
many aspects regarding the exact mechanism of action in health
and diseases still remain unknown (see Table 1). In this review, we
further discuss the current viewpoints and discoveries in the ﬁeld
of IL-32, focusing on the role of IL-32 in chronic inﬂammatory
diseases (RA, COPD and IBD) and atherosclerosis (Fig. 2).
3. IL-32 and inﬂammatory diseases
IL-32 has been reported to be involved in the pathogenesis of
chronic inﬂammatory diseases such as IBD, COPD and RA [21,22].
RA is often described as a standard prototype autoimmune disease.
It affects about 1% of the world population but the exact mecha-
nisms leading to RA still need to be deﬁned [23]. Cytokines play an
important role in the pathogenesis of this disease, with IL-6 and
TNFa being ones of the most studied so far. Therapeutic blockade of
these latter cytokines or their receptors improve the signs and
symptoms of RA, but is not able to cure the disease. Therefore, the
search for new mediators and pathways involved in the disease
onset and progression is worthwhile and could lead to new ther-
apeutic targets.
In line with this, a few years ago research started to focus on the
role of IL-32 in RA pathogenesis. A clear correlation between the IL-
32 protein expression in synovial tissue biopsies of RA patients and
disease activity has been demonstrated [8]. Apart from synovial
tissue macrophages, synovial ﬁbroblasts can produce TNFa, which
by itself is a potent inducer of IL-32 mRNA. Moreover, when IL-32
was overexpressed in these cells, mRNA transcripts of IL-1b and
TNFa were stabilized. Besides, when RA patients started anti-TNF
therapy, signiﬁcant lower levels of IL-32 were detected in syno-
vial tissue biopsies, suggesting a link between TNFa and IL-32 in RA
patients [24]. As a proof of concept, Joosten et al. injected recom-
binant human IL-32 into the joints of mice, inducing joint swelling,
inﬂux of pro-inﬂammatory cells and cartilage damage. This was
remarkably decreased when mice deﬁcient for TNFawere used [8].
Furthermore, to conﬁrm the pro-inﬂammatory effects of IL-32 in
human samples, experiments were performed using synovial tissue
biopsies and CD14þmonocytes obtained from both RA patients and
healthy individuals. mRNA levels of the most biologically active
isoform of IL-32, IL32g, were signiﬁcantly upregulated in speci-
mens of RA patients compared to healthy individuals [25]. Another
ﬁnding was the fact that IL-32 can synergize with soluble receptor
activator of NFk-B ligand (sRANKL) [26]. In cell cultures of
CD14þ monocytes from healthy volunteers treated with human
recombinant IL-32g, the presence of sRANKL resulted in an induced
osteoclast generation and tissue resorbtion. IL-32 alone was later
also found to be able to stimulate osteoclastogenesis without
RANKL [27]. Moreover, IL-32 levels were higher in ﬁbroblast-like
synoviocytes (FLS) from RA patients compared to FLS from osteo-
arthritis (OA) patients, strengthening the importance of IL-32 in
osteoclast differentiation and maturation from osteoclast pre-
cursors and activity [28]. In 2012, Moon et al. explored into more
detail the TNFa-dependent IL-32 induction in RA synovial ﬁbro-
blasts [27]. They found that the spleen tyrosine kinase (Syk)/protein
kinase Cd (PKCd)/c-Jun N-terminal kinase (JNK) pathways are
involved in the regulation. Inhibitors of Syk, PKCd and JNK were
able to suppress the TNFa-mediated induction of IL-32.
Besides this clear link with TNFa, IL-32 is also positively linked
to other inﬂammatory markers in RA [29]. IL-32 affects the pro-
duction of thymic stromal lymphopoietin (TSLP) in a monocyte
THP-1 cell line and PBMCs and by doing so inﬂuences monocyte
differentiation into macrophage-like cells, which can affect the
immune response [30]. In THP-1 cells or RA synovial ﬁbroblasts,
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overexpression of a splice-resistant IL-32gmutant resulted in more
IL-32g secretion and increased the level of the important cytokine
IL-1b. However, when IL-32b was overexpressed in these cells,
secretion of IL-32b was decreased and no clear induction of IL-1b
was observed [24]. These results suggest that IL-32b is a less active
pro-inﬂammatorymediator and that IL-32g splicing towards IL-32b
serves as a rescue mechanism to reduce inﬂammation.
Another isoform of IL-32 lacking exon 3 and 4 of the IL-32g
Table 1
The role of IL-32 and speciﬁc isoforms on the immune system and possible effects on the formation of atherosclerosis and increased risk for CVD.
Effect of IL-32 Implications in atherosclerosis/CVD
Produced by various cell types: endothelial cells, monocytes, ﬁbroblast-like
synoviocytes, B-cells, macrophages and T cells
Cells like monocytes, T cells and endothelial cells play an important role in
maintaining a normal environment in vessels. In atherosclerotic vessels function
of these cell types is disrupted
Affects cytokine production/regulation of pro-inﬂammatory cytokines like
TNFa, IL-6, IL-8, IL-1b
These cytokines are known to play a role in development of atherosclerosis and
CVD
Described to inﬂuence lipid composition; can affect HDL cholesterol levels A correct balance between lipoproteins is necessary to prevent the formation of
atherosclerosis and increased risk for CVD. HDL cholesterol is seen as anti-
atherogenic and should therefore protect against CVD
Speciﬁc effects of IL-32 isoforms
IL-32a - Most abundant form in hematopoietic cells
- Thought to be anti-inﬂammatory
IL-32b - Most abundant in endothelial cells
- Still pro-inﬂammatory but less than IL-32g
IL-32g - Induced in vitro endothelial cell tube formation
- Increases IL-1b from THP-1 and FLS
- Has anti-viral and anti-mycobacterial activities [65,66]
- Most pro-inﬂammatory and biologically active isoform [25]
Fig. 1. Schematic overview of intracellular IL-32 signaling pathways.
(A) IL-32 can synergize with NOD1 and NOD2 ligands like MDP, resulting in IL-6 and IL-1b production through a caspase-1-dependent mechanism. Signaling of MDP via NOD2 only
can also lead to activation of NF-kB via RIP2 signaling, leading to TNFa and IL-8 production. (B) IL-32 by itself can signal through p38 MAPK and NF-kB triggering TNFa and IL-8
production.
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isoform was identiﬁed in human colonic subepithelial myoﬁbro-
blasts (SEMFs) and named IL-32ε [31]. This isoform was enhanced
in the inﬂamed mucosa of inﬂammatory bowel disease (IBD) pa-
tients. Currently, the exact mechanisms underlying IBD are also not
completely known. Previously unidentiﬁed mediators such as IL-
32ε or components of the gut microﬂora have lately received
increasing attention in an attempt to understand the cascades of
inﬂammatory pathways during IBD [32,33]. Accordingly, Netea
et al. found that muramyl dipeptide (MDP), a peptidoglycan frag-
ment from bacteria and a potent NOD2 ligand, could induce the
expression of IL-32 in a caspase-1-dependent manner. Eventually,
this would result in an increased production of IL-6 and IL-1b
[20,34]. Interestingly, NOD2 mutations in Crohn's disease (CD)
patients were found to cause enhanced IL-1b and NF-kB activity,
importantly contributing to disease onset and its activity. These
ﬁndings suggest an important role for IL-32 in the progression and
pathophysiology of IBD, particularly in Crohn's disease (CD) [35]. In
IBD, IL-32 also correlates with TNFa levels. TNFa by itself was
shown to induce the IL-32ε isoform in these patients in a dose- and
time-dependent manner. However, IL-32ε was found to reduce
TNFa induced IL-8 transcript, whereas IL-32a did not show this
effect on IL-8 levels in the transfected human colon cancer cell line
HT-29 [21,31]. Additionally, in IL-32g transgenic mice, IL-32g
seemed to cause a greater and faster acute inﬂammation compared
to wild-type mice. However, there was a lower amount of colonic
inﬂammation and better survival rate upon dextran sodium sul-
phate (DSS)-induced colitis in these mice [32,36]. The lower
amount of inﬂammation could be explained by splicing of IL-32g
into IL-32b, which can induce IL-10 and creates a more anti-
inﬂammatory response [37]. Besides this, IL-32 in general not
only stimulates the production of pro-inﬂammatory cytokines from
monocytes, but also causes these monocytes to differentiate into
macrophages or dendritic cells [38]. Moreover, IL-32 can stimulate
neutrophils directly to produce IL-8 and IL-6 and indirectly recruits
T cells to inﬂamed areas in CD and IBD by production of other pro-
inﬂammatory cytokines by differentiated macrophages and DCs.
Eventually, inﬁltrating neutrophils will release a variety of
neutrophil proteinases resulting in mucosal tissue damage, aug-
menting inﬂammation in CD and IBD patients [21]. These data
show a wide variation in the effects of IL-32 isoforms on disease
progression and pathophysiology of IBD, and open new areas of
investigation into the pathophysiology of this disease.
It has been reported that IL-32 plays a role in chronic obstructive
pulmonary disease (COPD). COPD is described as a progressive
destructive disease occurring as an inﬂammatory response to toxic
particles or gases, mostly linked to excessive smoking. It is char-
acterized by airﬂow obstruction and persistent inﬂammation with
more than 90% of cases currently being caused by chronic cigarette
smoking [39]. Nevertheless, recent data shows a signiﬁcant prev-
alence of COPD in non-smokers, suggesting the contribution of
other factors to the pathogenesis of this disease, including envi-
ronmental factors [40]. Pathogenically, COPD is also not fully
elucidated. However, it is known that immune cells such as mac-
rophages, T cells and neutrophils are important players in the dis-
ease. Moreover, epithelial cells are described to be the major source
of inﬂammatory mediators in COPD. These cells are also known to
produce IL-32. Various factors including infection, proteases and
smoking can activate epithelial cells, triggering them to produce
growth factors as well as pro-inﬂammatory mediators, such as
TNFa, IL-12 and chemokines [41]. It has been indicated that IFNg is
able to induce IL-32 in human epithelial cells in a time-dependent
manner [16]. Moreover, in human bronchial epithelial cells, IFNg
induced IL-32 expression via the signaling pathway involving c-Jun
N-terminal kinases (JNK) but the inductionwas independent of p38
or mitogen-activated protein kinase (MEK) [39]. Interestingly,
smoking can also modulate IL-32 in epithelial cells in the airways.
Accordingly, COPD-affected smokers had higher IL-32 protein and
mRNA levels in lung tissue than non-COPD smokers and non-
smokers [22]. A correlation was shown between IL-32 lung tissue
levels and airﬂow obstruction in vivo. Increased IL-32 expression
Fig. 2. Chronic inﬂammatory diseases in which IL-32 is known to play an important role.
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levels showed a clear increase in immune response in COPD. Finally,
another study showed oxidative stress augmented the earlier
described IFNg-induced IL-32 expression in human bronchial
epithelial cells [39].
Taken together, these studies underline the potential patho-
physiologic role of IL-32 in various chronic inﬂammatory diseases.
In general, many IL-32 effects are TNFa dependent, but also direct
pro-inﬂammatory actions of IL-32 have also been suggested. It is of
high importance to elucidate the exact role of IL-32 in the patho-
logical disorders presented above and other chronic inﬂammatory
processes.
4. Chronic inﬂammation and cardiovascular disease
Cardiovascular (CV) morbidity and mortality are likely to be
increased in patients suffering from chronic inﬂammatory condi-
tions, e.g. RA, IBD and COPD. Traditional CV risk factors, however, do
not fully account for the increased CVD risk in these patients. Only
in the last decade, a clear relationship between chronic and sys-
temic inﬂammation and an increased CV risk has been established.
An increased burden of atherosclerosis in these patients has been
indicated to be responsible for the observed higher CV risk. Sub-
sequently, common pathophysiologic pathways to be shared by
atherosclerosis, as well as RA, IBD and COPD as inﬂammatory
conditions, have been hypothesized to explain the association of
the latter three with CVD. Atherosclerosis is increasingly seen as an
active inﬂammatory disease in which immune cells and systemic
markers of inﬂammation such as circulating antibodies, pro-
inﬂammatory cytokines such as IL-6, TNFa and IL-1b and immune
complexes play an important role in blood vessel pathology. The
hypothesis behind atherosclerosis being driven by inﬂammation is
consistent with the composition of the plaque and unstable coro-
nary lesions in which inﬂammatory cells and immune cells are
present at the shoulder region [42]. Many cell types that are
involved in both early and late-stage atherosclerosis also play a role
in the onset of RA, including endothelial cells, monocytes and
macrophages, B and T cells [43]. Additionally, increased pro-
inﬂammatory cytokine production and alterations in the Th1/Th2
cell ratio occur both in atherosclerosis and chronic inﬂammatory
diseases such as IBD and COPD [44]. Moreover, during chronic in-
ﬂammatory conditions such as RA, IBD and COPD, a non-resolving
inﬂammatory response is present in the human body. This in-
volves a dysbalance between various anti-inﬂammatory or reso-
lution factors and pro-inﬂammatory cytokines/mediators. In more
detail, this non-resolving status can be caused by impaired function
or numbers of anti-inﬂammatory or regulatory cells, inadequate
production of resolution factors such as IL-10, persistence of initi-
ating stimuli like lipids or excessive inﬂammatory responses that
form a positive feedback loop, maintaining inﬂammation [45,46].
Over time, this leads to endothelial damage of the arterial wall
Fig. 3. Schematic overview of the link between chronic inﬂammationeIL-32 and cardiovascular disease.
Chronic inﬂammation is the cause of these three diseases (RA, COPD, IBD) and is characterized by a persistent pro-inﬂammatory state. Various immune cells are involved, which
produce a wide variety of cytokines including IL-6, TNFa, IL-1b, IL-17, but also IL-32. These cytokines all contribute to changes in lipid levels and lipid composition resulting in (an
increased risk for) cardiovascular diseases.
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initiating and causing progression of atherosclerosis.
In acute coronary syndromes, plaques abound in IFNg, which is
mainly produced by CD4þ T cells that lack the co-stimulatory
molecule CD28 [47]. CD4þ T cells lacking CD28 are clonally
expanded in acute coronary syndromes and are known to invade
unstable atherosclerotic plaque regions resulting in weakening of
the ﬁbrous cap. Besides, CD4þ T cells can kill endothelial cells
in vitro, maybe leading to the described endothelial injury in cor-
onary plaques. Correspondingly, these CD4þ T cells lacking CD28
are also present in peripheral blood of RA patients, secreting Th1
associated-cytokines and possibly contributing to atherosclerotic
damage in these patients too [47,48]. Moreover, T cells can be
skewed toward the production of type II interferons (IFN) such as
IFNg. Together with the well known effects of matrix metal-
loproteinases (MMPs), these cells play a major role in joint
destruction as well as rupture of instable plaques [43].
The effects of immune dysregulation and chronic inﬂammation
are associated with endothelial activation and dysfunction, another
important contributor to atherosclerosis. When the endothelial
cells are exposed to these factors, the cells start to express adhesion
molecules, such as intercellular adhesion molecule 1 (ICAM-1),
selectins and vascular cell adhesion molecule 1 (VCAM-1) on their
cell surface [49]. Expression of adhesion molecules is induced by
pro-inﬂammatory mediators like TNFa, CRP and IL-1b, which are
also elevated in RA. In this respect, high-sensitivity CRP (hsCRP) has
been shown to be an independent risk factor for stroke and
myocardial infarction. Whether or not CRP has biological effects on
the development of atherosclerosis remains complex. Data on
hsCRP and its role in inﬂammation is massive and suggests a role
for hsCRP in the increased risk for atherosclerosis and CVD. Addi-
tionally, CRP may induce complement system activation and
endothelial cell production of VCAM-1, ICAM-1, IL-6, monocyte
chemotactic protein 1 (MCP-1) and endothelin-1 (ET-1) [50].
Another pro-atherogenic property of CRP is its capacity to stimulate
LDL uptake by macrophages, favouring foam-cell formation. How-
ever, Mendelian randomization studies have shown that hsCRP is
not a causal factor of CVD and even though it can be a useful
biomarker for risk prediction, hsCRP itself is unlikely to be a target
for intervention [51,52].
Next to these above-mentioned mechanisms, other very
important risk factors related to inﬂammation and auto-immunity
have been described as possible players in atherosclerosis. This also
includes endogenous self-molecules such as oxidized low-density
lipoprotein (ox-LDL), heat shock proteins (hsp), antibodies against
high-density lipoprotein cholesterol (HDLc) and apolipoprotein A-1
(ApoA-1). The latter two lipoproteins are known as anti-
atherogenic, and therefore antibodies against them are thought to
favour the development and progression of atherosclerosis [42]. In
general, cholesterol is an essential lipid in vertebrates, which is
crucial in, for example, cellular membranes, and cholesterol me-
tabolites like steroid hormones are important in physiological
functions [53]. Moreover, without the presence of excessive
cholesterol in the circulation and cholesterol accumulation in the
vessel walls, there would be no atherosclerosis. Various types of
lipoproteins and cholesterol take part in this process, with LDL
cholesterol (LDLc) being a well-known mediator contributing to
CVD. Traditionally, the atherogenic lipid proﬁle is made up of
increased total cholesterol (TC), LDLc, triglycerides (TG), and
decreased HDLc. In chronic inﬂammatory diseases such as RA,
however, different concentrations of lipids can be found
throughout different stages of the disease: increased TC and LDLc in
the years prior to disease onset, reduced levels of TC and HDLc
during early active disease, different patterns in established RA
[54,55]. It can, therefore, be concluded that inﬂammation is able to
directly affect cholesterol levels [56]. Perhaps even more
interesting, the ongoing inﬂammation is able to modulate the
cholesterol composition and may shift it to a more pro-atherogenic
proﬁle. In line with this, multiple groups have shown that HDL
becomes less anti-atherogenic in RA patients and this is associated
with an inﬂammatory status [57,58]. Therefore, during chronic in-
ﬂammatory conditions, HDL may lose its anti-atherogenic proper-
ties. Some of these functions include the capacity of HDL to prevent
oxidation of LDL, preventing inﬂammasome activation and sup-
pressing the expression of adhesion molecules such as VCAM-1 on
arterial endothelial cells. Unfortunately, it is known that HDL levels
may not reliably predict its composition and function and that
cholesterol efﬂux capacity is a better marker for HDL function [59].
Besides HDL, other cholesterol structures such as cholesterol crys-
tals (CC's), which are formed upon accumulation of free, unesteri-
ﬁed cholesterol inside the cells, also play a role in initiation of
atherosclerosis [60]. Cholesterol crystals can actually be found in all
stages of atherogenesis and are present in early atherosclerotic
lesions [61]. They can be phagocytosed by macrophages, which can
result in lysosomal damage and then trigger the activation of the
NACHT, LRR and PYD domains-containing protein 3 (NLRP3)
inﬂammasome. Eventually, this leads to activation of caspase-1 and
activation and secretion of IL-1b family cytokines [61,62]. Oxidized
LDL particles can also activate the NLRP3 inﬂammasome and
together with CC are potent inducers of IL-1b. Several studies
involving IL-1b deﬁciency in atherosclerotic mouse models have
shown attenuated disease progression, suggesting that cholesterol
crystal-induced NLRP3 inﬂammasome activation and IL-1b pro-
duction can drive atherogenesis [63,64].
Taken together, these studies support the important implication
of inﬂammation to the development of atherosclerosis and car-
diovascular diseases (CVD), both directly as well as by modulating
other organs (endothelial cells) and factors (lipoproteins) on which
the process of atherosclerosis is dependent. Various chronic in-
ﬂammatory conditions such as RA, IBD and COPD are likely to share
common pathophysiological pathways with atherosclerosis,
possibly explaining the increased CVD morbidity and mortality in
these patients.
5. The role of IL-32 in cardiovascular diseases/atherosclerosis
As mentioned before, atherosclerosis is a chronic inﬂammatory
process being the most studied determinant of CV morbidity and
mortality. Besides inﬂammation, risk factors like dyslipidemia also
play a role in progression. Knowing that inﬂammatory pathways
involved in the pathogenesis of chronic inﬂammatory diseases like
RA, IBD and COPD accelerate atherosclerosis, it is important to
study the role of the newly described pathways and the corre-
sponding cytokines involved also in the context of CVD and
atherosclerosis.
As already described, IL-32 is a pro-inﬂammatory cytokine
involved in the pathogenesis of RA. It promotes inﬂammation by
induction of other pro-inﬂammatory cytokines like IL-6, IL-1b, IL-8
and TNFa. Moreover, these cytokines are known to play a role in
atherogenesis. Additionally, in RA, as well as IBD and COPD, pro-
inﬂammatory cytokine TNFa is an important mediator of the dis-
ease. TNFa by itself is known to be associated with CVD and
atherosclerosis [67,68]. Furthermore, it was described previously
that IL-32 can induce TNFa and vice versa, creating a positive in-
ﬂammatory loop which might cause a non-resolving inﬂammatory
response contributing to a pro-atherogenic environment. In this
way, IL-32 by itself, and via induction of other pro-inﬂammatory
cytokines, is suggested to maintain an inﬂammatory response.
Besides this role for TNFa in atherogenesis, IL-6 is known to
contribute to thrombocytosis whereas IL-8 recruits immune cells to
the endothelial intima during all stages of plaque formation [69]. IL-
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1b plays a role in atherogenesis by acting on various aspects
involved in vascular inﬂammation. The endothelium is the primary
target of IL-1b by which its pro-inﬂammatory capacities inﬂuence
systemic inﬂammation. Additionally, IL-1b sets off the production
of IL-6, inhibitors of ﬁbrinolysis, prostaglandin E2 (PGE2) and
adhesion molecules in the endothelium, all of them participating in
pathological conditions [70]. Within these processes, an unex-
pected role for IL-32 was found. When IL-32 levels were decreased
by siRNA, the pro-coagulant, pro-inﬂammatory and cytokine effects
of IL-1b, like IL-1b-induced ICAM-1 production were also reduced
remarkably [11]. Therefore, IL-32 is hypothesized to also be an
important player in atherosclerosis. IL-32 expression was detected
in arterial vessel walls and another study showed expression in
endothelial cells induced by Akt, a protein kinase B involved in
apoptosis, cell proliferation, transcription and glucose metabolism
[12,71]. In hematopoietic cells, IL-32a is the most abundant form,
however, in endothelial cells, IL-32b was found mostly present
[16,71]. Knowing that the vascular endothelium is an important
mediator in inﬂammation, high levels of a pro-inﬂammatory iso-
form of IL-32 could contribute to its inﬂammatory state.
In addition to that, IL-32 is expressed inmacrophages, which are
highly present in atherosclerotic lesions. Macrophages showed a
highly increased mRNA and protein expression of IL-32 when
stimulated with pro-inﬂammatory mediators that are known to be
involved in atherosclerosis, including interferon-gamma (IFNg) and
a Toll-like receptor (TLR)3 ligand Poly I:C [72,73]. Moreover, mac-
rophages are key players in controlling cholesterol levels in blood
vessel walls. They take up cholesterol, can turn into foam cells, and
participate in the reverse cholesterol transport (RCT) by expressing
functional ATP-binding cassette transporter A1 (ABCA1) and ATP-
binding cassette transport G1 (ABCG1) [74]. Since macrophages
are able to express high levels of IL-32 and in the same time actively
regulate circulating cholesterol levels, one could hypothesize that
IL-32 may be somehow related to cholesterol concentrations.
Possibly, the intra-cellular capacities of IL-32 can interfere with the
regulation of cholesterol transporters or foam cell formation and
therefore inﬂuence circulating cholesterol levels. Despite previous
work describing the various isoforms of IL-32, the function of each
isoform is not completely clear yet. In addition, not a lot is known
about genetic mutations in IL32, especially at functional level.
Recently, it was described that a single nucleotide polymorphism
(SNP) in the promoter region of IL32 that seems to affect the
expression of the isoforms in peripheral blood mononuclear cells
(PBMCs). RA patients with this SNP had lower basal levels of IL-32b
compared to RA patients with the other genotypes. This was also
linked to lower cytokine production of PBMCs after stimulation
[75]. Intriguingly, it was also demonstrated that this promoter SNP
in IL32 is associated with higher levels of high-density cholesterol
(HDLc) [76]. This mutation in the IL32 gene could therefore
contribute to a lower risk for CVD in patients with chronic in-
ﬂammatory diseases like RA and IBD in which IL-32 is known to
play a role.
6. Concluding remarks and future perspectives
In this review, important advances in the ﬁeld of chronic
inﬂammation and cardiovascular diseases with respect to IL-32 are
discussed (Fig. 3). A light was shed on the role of a relatively new
cytokine IL-32 in chronic inﬂammatory disorders. On the basis of
recent reports, IL-32may prove to be a crucial player when it comes
to reducing the burden of systemic inﬂammation in the future.
Another important ﬁnding was the identiﬁcation of a genetic
polymorphism in the promoter of IL-32, which affects cholesterol
metabolism, possibly decreasing CVD risk. Interestingly, this SNP
also affects the isoform expression in PBMCs, including macro-
phages. Future studies should be focused on whether individuals
bearing this SNP would be less prone to develop cardiovascular
diseases. In addition, studies on the function of IL-32 in cholesterol
metabolism should be initiated well in the near future. Of high
interest, possible therapeutic effects of speciﬁc inhibitors against
IL-32 isoforms to interfere with the development of atherosclerosis
should be considered.
In conclusion, the above results not only provide novel insight in
the cytokine IL-32 and its role in inﬂammation, but also propose
important reasons why IL-32 should be taken into account when
studying the development of cardiovascular diseases. Eventually,
this could expand our understanding of the processes underlying
CVD in both health and disease.
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